絞り込み

18451

広告

「核ごみ」国、初の住民説明会 理解求める 北海道・神恵内村 (毎日新聞)

高レベル放射性廃棄物(核のごみ)最終処分場の選定に向けた文献調査応募の動きがある北海道神恵内(かもえない)村で26日夜、資源エネルギー庁と原子力発電環境整備機構...

  1. 「日韓交流おまつり」初のオンライン開催 ...
  2. [医学] HIV感染の恐れが大きい人の1...
  3. [医学] PTEN欠損胆管細胞癌にプロテ...
  4. [医学] α1抗トリプシン欠乏変異の人が...

ニュース一覧

A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response.

著者 Bilgetekin I , Mammadkhanli O , Basal FB , Kandemir O , Canbay S , Oksuzoglu B
Anticancer Drugs.2019 Nov 15 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (35view , 0users)
Although giant cell tumor of bone has been considered as a disease with benign course, it can lead to bone destruction and serious morbidity. A 19-year-old case was presented with hip pain. There was a recurrence after 9 months of curative surgical resection and zoledronic acid use, and as surgical morbidity would be high, antiosteoclastic receptor activator of nuclear factor kappa B ligand inhibitor denosumab treatment was administered. She had a complete remission after 18 months of denosumab treatment. The important point in the present case is that it has been followed up without recurrence after around 42 months of denosumab use and 11 months of follow-up after the cessation of drug. In recurrent cases in which nonmetastatic surgery is not suitable, the use of denosumab decreases tumor progression. The duration of use in unresectable and advanced cases still remains unclear.
PMID: 31743134 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード